Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36

Loading news article.

Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36 | WAPE

Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36

Article summary

Related companies

Comments —